| Nov 14 |
Is AstraZeneca a Buy as It Eyes the Weight Loss Market?
|
| Nov 14 |
China has trapped the tiger of AstraZeneca’s growth
|
| Nov 13 |
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
|
| Nov 13 |
Q3 2024 FibroGen Inc Earnings Call
|
| Nov 13 |
Merck and AstraZeneca announce results of Koselugo in neurofibromatosis trial
|
| Nov 13 |
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing
|
| Nov 13 |
AstraZeneca invests $3.5B in US manfacturing, R&D
|
| Nov 13 |
MSD and AstraZeneca report positive topline data from Koselugo trial for NF1
|
| Nov 13 |
AstraZeneca plans major $3.5bn expansion drive in the US
|
| Nov 13 |
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
|
